BusinessWeek profiles Margaret McGlynn (photo [1]), president of Merck Vaccines for the past 14 months. During that time, Merck has launched four vaccines, including Gardasil as a protection against cervical cancer. These vaccines are at the center of Merck's plans to revive the company from its post-Vioxx debacle. Gardasil alone is expected to generate $2 billion to $4 billion in annual revenue.
- here's the BusinessWeek report [2] on McGlynn
Related Articles:
Merck's Gardasil OK'd for pricey rollout. Report [3]
Idera inks $455M pact for Merck vaccines. Report [4]
Links:
[1] http://www.fiercebiotech.com/node/5066
[2] http://www.businessweek.com/magazine/content/07_02/b4016074.htm
[3] http://www.fiercebiotech.com/story/merck-s-gardasil-ok-d-for-pricey-rollout/2006-06-09
[4] http://www.fiercebiotech.com/story/idera-inks-455m-pact-for-merck-vaccines/2006-12-11